Morgan Stanley Downgrades Integra Lifesciences to Underweight, Announces $44 Price Target
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Drew Ranieri has downgraded Integra Lifesciences (NASDAQ:IART) from Equal-Weight to Underweight and set a price target of $44.
August 24, 2023 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra Lifesciences has been downgraded by Morgan Stanley from Equal-Weight to Underweight with a price target of $44.
The downgrade from Morgan Stanley is a negative signal for Integra Lifesciences. The new rating of Underweight suggests that the analyst believes the stock will underperform the market. The price target of $44 also indicates a potential downside from the current price. This could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100